MannKind Corp Analyst Report; Afrezza is Approved and Future Developments by BrokerBank Securities, Inc.

NEW YORK, July 3, 2014 /PRNewswire/ -- MannKind Corporation MNKD is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The company's lead product – Afrezza inhalation powder – was recently approved by the FDA as a rapid-acting insulin therapy intended to improve glycemic control in adults with type 1 or type 2 diabetes. MannKind was founded by Al Mann for the purpose of developing inhaled insulin as an alternative to traditional injected insulin.

The World Health Organization (WHO) estimates that approximately 382 million people worldwide have diabetes with roughly 3.4 million cases leading to death. The US accounts for the third largest number of confirmed diabetes cases in the world at around 30 million, with China and India leading with around 92 million and 80 million, respectively. However, the portion of the population with diabetes is the highest in the US than in either of those countries. Additionally, diabetes is currently the seventh leading cause of death in the US, and WHO projects that the number of diabetes-related deaths will double by the year 2030. Worldwide, the total costs for diabetes treatment and care exceeded $548B last year, and is only expected to increase as more and more people are diagnosed in the future.

A full in-depth analyst report on MNKD that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-MNKD-AnalystReport

Copy and paste to browser may be required.

This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form. A full disclaimer can be found by viewing the full analyst report.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mike Maggi, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.